A review of cancer risk prediction models with genetic variants

Xuexia Wang, Michael J Oldani, Xingwang Zhao, Xiaohui Huang, Dajun Qian, Xuexia Wang, Michael J Oldani, Xingwang Zhao, Xiaohui Huang, Dajun Qian

Abstract

Cancer risk prediction models are important in identifying individuals at high risk of developing cancer, which could result in targeted screening and interventions to maximize the treatment benefit and minimize the burden of cancer. The cancer-associated genetic variants identified in genome-wide or candidate gene association studies have been shown to collectively enhance cancer risk prediction, improve our understanding of carcinogenesis, and possibly result in the development of targeted treatments for patients. In this article, we review the cancer risk prediction models that have been developed for popular cancers and assess their applicability, strengths, and weaknesses. We also discuss the factors to be considered for future development and improvement of models for cancer risk prediction.

Keywords: cancer; cancer intervention; cancer risk prediction; genetic variants; risk prediction models.

References

    1. de Martel C, Ferlay J, Franceschi S, et al. Global burden of cancers attributable to infections in 2008: a review and synthetic analysis. Lancet Oncol. 2012;13:607–15.
    1. Schully SD, Yu W, McCallum V, et al. Cancer GAMAdb: database of cancer genetic associations from meta-analyses and genome-wide association studies. Eur J Hum Genet. 2011;19:928–30.
    1. Stadler ZK, Vijai J, Thom P, et al. Genome-wide association studies of cancer predisposition. Hematol Oncol Clin North Am. 2010;24:973–96.
    1. Lu K, Kauff N, Powell CB, et al. Hereditary Breast and Ovarian Cancer Syndrome. ACOG PRACTICE BULLETIN. Obstet Gynecol. 2009;113:957–66.
    1. Gail MH, Brinton LA, Byar DP, et al. Projecting individualized probabilities of developing breast cancer for white females who are being examined annually. J Natl Cancer Inst. 1989;81:1879–86.
    1. Gail MH, Benichou J. Validation studies on a model for breast cancer risk. J Natl Cancer Inst. 1994;86:573–5.
    1. Wacholder S, Hartge P, Prentice R, et al. Performance of common genetic variants in breast-cancer risk models. N Engl J Med. 2010;362:986–93.
    1. Machiela MJ, Chen CY, Chen C, Chanock SJ, Hunter DJ, Kraft P. Evaluation of polygenic risk scores for predicting breast and prostate cancer risk. Genet Epidemiol. 2011;35:506–14.
    1. Antoniou AC, Beesley J, McGuffog L, et al. Common breast cancer susceptibility alleles and the risk of breast cancer for BRCA1 and BRCA2 mutation carriers: implications for risk prediction. Cancer Res. 2010;70(23):9742–54.
    1. Chenevix-Trench G, Milne RL, Antoniou AC, Couch FJ, Easton DF, Goldgar DE. An international initiative to identify genetic modifiers of cancer risk in BRCA1 and BRCA2 mutation carriers: the Consortium of Investigators of Modifiers of BRCA1 and BRCA2 (CIMBA) Breast Cancer Res. 2007;9:104.
    1. Sueta A, Ito H, Kawase T, et al. A genetic risk predictor for breast cancer using a combination of low-penetrance polymorphisms in a Japanese population. Breast Cancer Res Treat. 2012;132:711–21.
    1. Lichtenstein P, Holm NV, Verkasalo PK, et al. Environmental and heritable factors in the causation of cancer-analyses of cohorts of twins from Sweden, Denmark, and Finland. N Engl J Med. 2000;343:78–85.
    1. Amundadottir LT, Thorvaldsson S, Gudbjartsson DF, et al. Cancer as a complex phenotype: pattern of cancer distribution within and beyond the nuclear family. PLoS Med. 2004;1(3):e65.
    1. Goh CL, Eeles RA. Germline genetic variants associated with prostate cancer and potential relevance to clinical practice. prostate cancer prevention. Recent Results Cancer Res. 2014;202:9–26.
    1. Xu J, Sun J, Kader AK, et al. Estimation of absolute risk for prostate cancer using genetic markers and family history. Prostate. 2009;69:1565–72.
    1. Sun J, Kader AK, Hsu FC, et al. Inherited genetic markers discovered to date are able to identify a significant number of men at considerably elevated risk for prostate cancer. Prostate. 2011;71:421–30.
    1. Johansson M, Holmstrom B, Hinchliffe SR, et al. Combining 33 genetic variants with prostate-specific antigen for prediction of prostate cancer: Longitudinal study. Int J Cancer. 2012;130:129–37.
    1. Evans DM, Visscher PM, Wray NR. Harnessing the information contained within genome-wide association studies to improve individual prediction of complex disease risk. Hum Mol Genet. 2009;18:3525–31.
    1. Kote-Jarai Z, Easton DF, Stanford JL, et al. Multiple novel prostate cancer predisposition loci confirmed by an international study: the PRACTICAL Consortium. Cancer Epidemiol Biomarkers Prev. 2008;17:2052–61.
    1. Macinnis RJ, Antoniou AC, Eeles RA, et al. A risk prediction algorithm based on family history and common genetic variants: application to prostate cancer with potential clinical impact. Genet Epidemiol. 2011;35:549–56.
    1. Al Olama AA, Kote-Jarai Z, Giles GG, et al. Multiple loci on 8q24 associated with prostate cancer susceptibility. Nat Genet. 2009;41:1058–60.
    1. Lindström S, Schumacher FR, Cox D, et al. Common genetic variants in prostate cancer risk prediction – results from the NCI Breast and Prostate Cancer Cohort Consortium (BPC3) Cancer Epidemiol Biomarkers Prev. 2012;21(3):437–44.
    1. Dieckmann KP, Pichlmeier U. The prevalence of familial testicular cancer: an analysis of two patient populations and a review of the literature. Cancer. 1997;80:1954–60.
    1. Forman D, Oliver RT, Brett AR, et al. Familial testicular cancer: a report of the UK family register, estimation of risk and an HLA class 1 sib-pair analysis. Br J Cancer. 1992;65:255–62.
    1. Heimdal K, Olsson H, Tretli S, Flodgren P, Borresen AL, Fossa SD. Familial testicular cancer in Norway and southern Sweden. Br J Cancer. 1996;73:964–9.
    1. Hemminki K, Chen B. Familial risks in testicular cancer as a etiological clues. Int J Androl. 2009;29:205–10.
    1. Hemminki K, Li X. Familial risk in testicular cancer as a clue to a heritable and environmental etiology. Br J Cancer. 2004;90:1765–70.
    1. Czene K, Lichtenstein P, Hemminki K. Environmental and heritable causes of cancer among 9.6 million individuals in the Swedish Family-Cancer Database. Int J Cancer. 2002;2002;99:260–6.
    1. Nathanson KL, Kanetsky PA, Hawes R, et al. The Y deletion gr/gr and susceptibility to testicular germ cell tumor. Am J Hum Genet. 2005;77:1034–43.
    1. Kanetsky PA, Mitra N, Vardhanabhuti S, et al. Common variation in KITLG and at 5q31.3 predisposes to testicular germ cell cancer. Nat Genet. 2009;41:811–5.
    1. Kanetsky PA, Mitra N, Vardhanabhuti S, et al. A second independent locus within DMRT1 is associated with testicular germ cell tumor susceptibility. Hum Mol Genet. 2011;20:3109–17.
    1. Rapley EA, Turnbull C, Al Olama AA, et al. A genome-wide association study of testicular germ cell tumor. Nat Genet. 2009;41:807–10.
    1. Turnbull C, Rapley EA, Seal S, et al. Variants near DMRT1, TERT and ATF7IP are associated with testicular germ cell cancer. Nat Genet. 2010;42:604–7.
    1. Kratz CP, Greene MH, Bratslavsky G, Shi J. A stratified genetic risk assessment for testicular cancer. Int J Androl. 2011;34:e98–102.
    1. Dieckmann KP, Pichlmeier U. Clinical epidemiology of testicular germ cell tumors. World J Urol. 2004;22:2–14.
    1. Li X, Hemminki K. Familial and second lung cancers: a nation-wide epidemiologic study from Sweden. Lung Cancer. 2003;39:255–63.
    1. Jonsson S, Thorsteinsdottir U, Gudbjartsson DF, et al. Familial risk of lung carcinoma in the Icelandic population. JAMA. 2004;292:2977–83.
    1. McKay JD, Hung RJ, Gaborieau V, et al. Lung cancer susceptibility locus at 5p15.33. Nat Genet. 2008;40:1404–6.
    1. Rafnar T, Sulem P, Stacey SN, et al. Sequence variants at the TERT-CLPTM1L locus associate with many cancer types. Nat Genet. 2009;41:221–7.
    1. Amos CI, Wu X, Broderick P, et al. Genome-wide association scan of tag SNPs identifies a susceptibility locus for lung cancer at 15q25.1. Nat Genet. 2008;40:616–22.
    1. Hung RJ, McKay JD, Gaborieau V, et al. A susceptibility locus for lung cancer maps to nicotinic acetylcholine receptor subunit genes on 15q25. Nature. 2008;452:633–7.
    1. Thorgeirsson TE, Geller F, Sulem P, et al. A variant associated with nicotine dependence, lung cancer and peripheral arterial disease. Nature. 2008;452:638–42.
    1. Wang Y, Broderick P, Webb E, et al. Common 5p15.33 and 6p21.33 variants influence lung cancer risk. Nat Genet. 2008;40:1407–9.
    1. Bach PB, Kattan MW, Thornquist MD, et al. Variations in lung cancer risk among smokers. J Natl Cancer Inst. 2003;95:470–8.
    1. Cassidy A, Myles JP, van Tongeren M, et al. The LLP risk model: an individual risk prediction model for lung cancer. Br J Cancer. 2008;98:270–6.
    1. Spitz MR, Hong WK, Amos CI, et al. A risk model for prediction of lung cancer. J Natl Cancer Inst. 2007;99:715–26.
    1. Tammemagi CM, Pinsky PF, Caporaso NE, et al. Lung cancer risk prediction: prostate, lung, colorectal and ovarian cancer screening trial models and validation. J Natl Cancer Inst. 2011;103:1058–68.
    1. Raji O, Agbaje OF, Duffy SW, Cassidy A, Field JK. Incorporation of a genetic factor into an epidemiologic model for prediction of individual risk of lung cancer: the Liverpool Lung Project. Cancer Prev Res. 2010;3:664–9.
    1. Raji O, Duffy SW, Agbaje OF, et al. Predictive accuracy of the liverpool lung project risk model for stratifying patients for computed tomography screening for lung cancer: a case-control and Cohort validation study. Ann Intern Med. 2012;157(4):242–50.
    1. Li H, Yang L, Zhao X, et al. Prediction of lung cancer risk in a Chinese population using a multifactorial genetic model. BMC Med Genet. 2012;13:118.
    1. Etzel CJ, Kachroo S, Liu M, et al. Development and validation of a lung cancer risk prediction model for African-Americans. Cancer Prev Res (Phila) 2008;1:255–65.
    1. Spitz MR, Amos CI, Land S, et al. Role of selected genetic variants in lung cancer risk in African Americans. J Thorac Oncol. 2013;8:391–7.
    1. Wu X, Lin J, Grossman HB, et al. Projecting individualized probabilities of developing bladder cancer in white individuals. J Clin Oncol. 2007;25:4974–81.
    1. Chen M, Cassidy A, Gu J, et al. Genetic variations in PI3 K-AKT-mTOR pathway and bladder cancer risk. Carcinogenesis. 2009;30(12):2047–52.
    1. Garcia-Closas M, Rothman N, Figueroa JD, et al. Common genetic polymorphisms modify the effect of smoking on absolute risk of bladder cancer. Cancer Res. 2013;73:2211–20.
    1. Neumann AS, Sturgis EM, Wei Q. Nucleotide excision repair as a marker for susceptibility to tobacco-related cancers: a review of molecular epidemiological studies. Mol Carcinog. 2005;42:65–92.
    1. Friedberg EC. How nucleotide excision repair protects against cancer. Nat Rev Cancer. 2001;1:22–33.
    1. Goode EL, Ulrich CM, Potter JD. Polymorphisms in DNA repair genes and associations with cancer risk. Cancer Epidemiol Biomarkers Prev. 2002;11:1513–30.
    1. McKay JD, Truong T, Gaborieau V, et al. A genome-wide association study of upper aerodigestive tract cancers conducted within the INHANCE consortium. PLoS Genet. 2011;7:e1001333.
    1. Hashibe M, McKay JD, Curado MP, et al. Multiple ADH genes are associated with upper aerodigestive cancers. Nat Genet. 2008;40:707–9.
    1. Wyss Annah B, Herring Amy H, Avery Christy L, et al. Single-Nucleotide polymorphisms in nucleotide excision repair genes, cigarette smoking, and the risk of head and neck cancer. Cancer Epidemiol Biomarkers Prev. 2013;22:1428–45.
    1. Wyss AB, Herring AH, Avery CL, et al. Single-nucleotide polymorphisms in nucleotide excision repair genes, cigarette smoking, and the risk of head and neck cancer. Cancer Epidemiol Biomarkers Prev. 2013;22:1428–45.
    1. Yuan H, Ma H, Lu F, et al. Genetic variants at 4q23 and 12q24 are associated with head and neck cancer risk in China. Mol Carcinog. 2013;52:e2–9.
    1. Wu X, Spitz MR, Lee JJ, et al. Novel susceptibility loci for second primary tumors/recurrence in head and neck cancer patients: large scale evaluation of genetic variants. Cancer Prev Res (Phila) 2009;2(7):617–24.
    1. International Schizophrenia Consortium. Purcell SM, Wray NR, et al. Common polygenic variation contributes to risk of schizophrenia and bipolar disorder. Nature. 2009;460:748–52.
    1. Bahcall O. Risk prediction and population screening for breast, ovarian and prostate cancers. 2014 doi: 10.1038/ngicogs.5.
    1. Moons KGM, Kengne AP, Woodward M, Royston P, et al. Risk prediction models: I. Development, internal validation, and assessing the incremental value of new (bio)marker. Heart. 2012;98:683–90.
    1. Dudbridge F. Power and Predictive Accuracy of Polygenic Risk Scores. PLoS Genet. 2013;9(3):e1003348. doi: 10.1371/journal.pgen.1003348.

Source: PubMed

Спонсоры и соавторы

Заболевания

Медикаментозные вмешательства

Подписаться